DefiniGEN is a spin-out from the University of Cambridge, creating highly predictive disease cell models for preclinical research and drug development. The process of bringing new drugs to market is arduous, expensive and blighted by a high failure rate. DefiniGEN’s models help the biopharma industry to respond to these challenges, enabling highly relevant information on potential new drug efficacy to be realised in an accelerated manner.
Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth.Dr Marcus Yeo , CEO
Business funding insights
A decade of hard work coming to fruition? Just look at our investments and exits
Far from slowing down as a result of the coronavirus pandemic, BGF’s investment activity has stepped up both in pace and volume.
Exit strategies: how to get the timing and valuation right
More than 100 BGF-backed businesses have achieved exits. Our panel of experts discuss the exit strategies that are proven to succeed.